Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Trending Topics

    business

    Trump's 'Make in US' plan a worry for pharma cos: Surajit Pal

    In conversation with CNBC-TV18, Surajit Pal, Prabhudas Lilladher, said Cipla's numbers are in line with the estimates but the company is still in the transition phase.

    first published: Nov 10, 2016 10:42 am

    LATEST VIDEOS

    Watch More →

    A collection of the most-viewed Moneycontrol videos.

    Watch and Follow our leading shows

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347